Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Aspen vs LillyDirect Foundayo

Aspen
Graded #372

Lower grade

vs+8.800000000000004
LillyDirect Foundayo
Graded #165

Higher grade

The verdict

LillyDirect Foundayo takes it — 67.2/100 to 58.4/100.

LillyDirect Foundayo grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Eli Lilly's manufacturer direct-pay channel for Foundayo (orforglipron), the first oral GLP-1 pill for weight loss.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueLillyDirect Foundayo +45
27
72
Dose & formulationAspen +5
64
59
Clinical oversightAspen +2
80
78
Labs & monitoringEven
52
52
FulfillmentAspen +14
94
80
Contract termsLillyDirect Foundayo +8
47
55
Aspen · left barLillyDirect Foundayo · right bar

The numbers

MetricAspenLillyDirect Foundayo
WeighScore58.4/10067.2/100
GradeCC
Scorecard rank#372#165
Semaglutide$279/mo (3-month plan, compounded)Not disclosed
Tirzepatide$399/mo (compounded)Not disclosed
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
Aspen

Graded #372 · C

Strengths

  • LegitScript-certified with an independently verifiable seal (#50306023) and HIPAA compliance — a strong trust signal for a compounded-GLP-1 telehealth
  • Names its dispensing pharmacy: Red Rock Compounding Pharmacy, LegitScript-certified and NABP-accredited, licensed in 49 states plus DC
  • Flat pricing at every dose ("same price at every dose, no surprises") plus free expedited shipping, so your cost won't rise as you titrate up
  • Competitive prepay rates — compounded semaglutide as low as $179/mo (12-mo) and tirzepatide $299/mo — with zero interest and no credit check
  • Money-back guarantee for qualifying patients who complete the full 28-week program without losing weight; available in all 50 states + DC

Where it loses points

  • Compounded semaglutide and tirzepatide only — no brand-name Wegovy, Zepbound or Ozempic — and compounded GLP-1s aren't FDA-reviewed or approved
  • Even the "monthly" plan requires a 3-month commitment with three months of medication shipped and billed upfront — limited month-to-month flexibility
  • Standing month-to-month pricing is steep ($279 semaglutide, $399 tirzepatide); the lowest rates require 6- or 12-month prepay
  • The provider chooses semaglutide vs tirzepatide for you, so you can't freely pick your own molecule
  • Registered as Aspen Health Systems LLC at a Sheridan, WY address; async model with no routine video visit
LillyDirect Foundayo

Graded #165 · C

Strengths

  • Cheapest legal path to a brand-name GLP-1 in 2026 ($25/mo with savings card for commercial insurance)
  • Direct from manufacturer — no compounding, no third-party reseller
  • Daily oral pill, no injections, no refrigeration
  • Available in all 50 states

Where it loses points

  • Lower mean weight loss vs Wegovy (14.9%) and Zepbound (20.9%) — labeled-dose 11.1% per Foundayo PI
  • Requires existing prescription from a separate prescriber (LillyDirect does not write the prescription)
  • $25 savings card requires commercial insurance — Medicare and Medicaid not eligible
  • Strict empty-stomach 30-minute window may be hard for some patients to follow

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard